Complex I Modulators Inhibiting ROS Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments fail to effectively inhibit reactive oxygen species (ROS) generation by mitochondrial Complex I, which is implicated in various diseases associated with oxidative stress, including neurological disorders and mitochondrial diseases.
Innovation Solution
Development of compounds that modulate the function of mitochondrial Complex I, specifically inhibiting ROS formation by targeting the enzyme to treat or prevent conditions related to oxidative stress, using a pharmaceutical composition that includes specific chemical compounds formulated to interact with Complex I.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments are used, then existing therapies can be administered, but they fail to effectively inhibit ROS generation by Complex I
Solution Approach 1:
The patent modifies the chemical structure of Complex I inhibitors by changing molecular parameters such as introducing specific heterocyclic rings (pyridine, pyrimidine, triazine), adjusting substituent groups (halogen atoms, alkyl chains, aromatic groups), and optimizing molecular weight and lipophilicity to achieve effective ROS inhibition that conventional treatments cannot accomplish
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups and structural motifs within single compound molecules, integrating electron-transfer capable groups with membrane-permeable moieties and ROS-scavenging functional groups to achieve synergistic therapeutic effects
2Object-affected harmful factors
If Complex I is inhibited to reduce ROS, then oxidative stress is reduced, but the enzyme function is disrupted
Solution Approach 1:
The patent employs partial inhibition strategies where the compounds selectively inhibit Complex I to sufficient extent to reduce ROS generation and oxidative stress, while maintaining enough residual function to preserve mitochondrial ATP synthesis and basic respiratory activity, avoiding complete enzymatic shutdown
Solution Approach 2:
The invention exploits the harmful electron leakage and superoxide formation at the NADH-binding site of Complex I by introducing compounds that target this specific location, converting the harmful ROS generation mechanism into a therapeutic target where inhibition of electron transfer reduces oxidative stress without completely blocking mitochondrial function
3Reliability
If new compounds are developed to modulate Complex I, then therapeutic effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent divides the complex molecule into distinct functional segments: electron-transfer capable groups (pyridine, pyrimidine rings), membrane-permeable moieties (lipophilic side chains, aromatic groups), and ROS-scavenging functional groups (hydroxyl, carboxyl, amine groups), allowing systematic design and optimization of each segment independently
Solution Approach 2:
The invention designs multi-functional compounds that simultaneously perform multiple roles: acting as electron transfer inhibitors, ROS scavengers, and membrane permeable agents, reducing the need for multiple separate therapeutic agents and simplifying the overall treatment approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce ROS generation by Complex I, providing therapeutic benefits for a range of diseases linked to oxidative stress, including neurological and mitochondrial disorders, by lowering oxidative stress levels.
Implementation Method 1
One major source of ROS is oxidative phosphorylation via Complex I. The enzyme is a protein complex, encoded by 39 nuclear and 7 mitochondrial genes which is expressed ubiquitously and transfers electrons from NADH to Ubiquinone, coupled to translocation of protons necessary for ATP synthesis.
Implementation Method 2
transfers electrons from NADH to Ubiquinone, coupled to translocation of protons necessary for ATP synthesis
Implementation Method 3
The cytotoxic O2·− generated by Complex I is detoxified mainly by the mitochondrial superoxide dismutase (SOD2), generating hydrogen peroxide which is detoxified by a variety of enzymes, such as Catalase, Glutathionperoxidase(s), Thioreredoxin(s) etc.
Data Source
AI summary
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)